ISARIC provides a collaborative platform through which global, patient‐oriented clinical studies can be developed, executed and shared.

Protocols addressing the most important questions between and during epidemics of severe acute respiratory infections and other rapidly emerging public health threats are undertaken in order to generate new knowledge, maximise the availability of clinical information, and thereby save lives.

Healthcare professionals in COVID-19 hospital (Photo credit: Professor Bin Cao, China-Japan Friendship Hospital, China)

International Severe Acute Respiratory and emerging Infection Consortium

What we do

Our purpose is to prevent illness and deaths from infectious disease outbreaks.

We are a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases.

COVID-19 resources:

In December 2019, a novel coronavirus (SARS-CoV-2) emerged to cause a pandemic of a severe coronavirus disease (COVID-19). ISARIC has created tools for investigators to collect and store data in a standardised way and has supported clinical trials of treatments.

Publication library

Visit this section to find ISARIC’s articles, studies and more.

See below our featured research areas: 

COVID-19 CCP

COVID-19
Follow-up study

Lassa fever

Ebola
Data Tools

If you want to use these research tools or if you require further information, please contact the ISARIC team: gsc@isaric.org

Latest news

Women under 50 had worse long-term outcomes after hospitalisation with COVID-19

Women under 50 had worse long-term outcomes after hospitalisation with COVID-19

Women under 50 and people who experienced severe disease had worse long-term outcomes following hospitalisation with COVID-19.

Key inflammatory markers identified in COVID-19

Key inflammatory markers identified in COVID-19

ISARIC, supported by the UK Coronavirus Immunology Consortium (UK-CIC), has identified new biomarkers of inflammation that both indicate the severity of COVID-19 and distinguish it from severe influenza.

Long COVID: tackling a multifaceted condition requires a multi- disciplinary approach

Long COVID: tackling a multifaceted condition requires a multi- disciplinary approach

The Lancet Infectious Diseases  published the GloPID-R and ISARIC Long COVID Forum Working Group’ letter, describing the content and discussions of the Long COVID Forum which took place on 9-10 December 2020.

Non-invasive ventilation strategies in COVID-19 – sharing experiences

Non-invasive ventilation strategies in COVID-19 – sharing experiences

Event date - 17/12/2020

This forum aims to review evidence and strategies for Non-invasive ventilation (NIV) in COVID, develop and promote research ideas and evidence-based practice.

Long COVID Forum: 9-10 December 2020

Long COVID Forum: 9-10 December 2020

Event date - 09/12/2020

Currently very little is known about the clinical, biological, psychological and socio-environmental impact of Coronavirus Disease 2019 (COVID-19). While most people have uncomplicated recoveries, some continue to live with prolonged illness and symptoms.

How India is identifying best practice in the use of Corticosteroids in COVID-19

How India is identifying best practice in the use of Corticosteroids in COVID-19

Event date - 26/11/2020

ISARIC partners have been at the forefront of clinical trials of COVID-19 treatments since the start of the pandemic. Recognising how hard it is to keep up with the extraordinary pace of COVID science, ISARIC will run a series of ‘Evidence Fora’ on COVID-19 treatment.

/ˌi.ˈsɑ.rɪk/ ("ee-sa-ric")

From Aramaic איסריא (isaraya), "a bondsman;"

from base word איסרא (isara), "a bond, tie, or binding;"

from Aramaic root אסר (asr), "to bind"